New drug trial aims to keep aggressive breast cancer at bay
NCT ID NCT07321015
Summary
This study tests whether a drug called fluzoparib can help control advanced triple-negative breast cancer after initial treatment. It will involve 72 patients whose cancer responded to platinum-based chemotherapy but could still return. The goal is to see if taking fluzoparib as maintenance therapy can delay cancer progression and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Conditions
Explore the condition pages connected to this study.